BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

RARE upcoming catalysts

Ultragenyx Pharmaceutical Inc: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 3 FDA event(s). Subscribe to RARE (.ics).

Drugs: GTX-102, setrusumab

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01 est.P3Ultragenyx Pharmaceutical Inc RARENCT06636071 Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaOsteogenesis Imperfectaactive not recruiting6

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-09-19PDUFA date (company-disclosed)date passedUltragenyx Pharmaceutical Inc. RAREapazunersenPDUFA September 19, 2026 - Ultragenyx Pharmaceutical Inc. (apazunersen)
2026-08-23PDUFA date (company-disclosed)date passedUltragenyx Pharmaceutical Inc. RARErebisufligenePDUFA August 23, 2026 - Ultragenyx Pharmaceutical Inc. (rebisufligene)
2026-07-01 (half)PDUFA date (company-disclosed)date passedUltragenyx Pharmaceutical Inc. RAREPDUFA second half of 2026 - Ultragenyx Pharmaceutical Inc.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-30P2Ultragenyx Pharmaceutical Inc RARENCT07157254 A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)Angelman Syndrometerminated55
2026-10-30P3Ultragenyx Pharmaceutical Inc RARENCT06415344 Long-term Extension of GTX-102 in Angelman SyndromeAngelman Syndrometerminated66
2026-07-10P3Ultragenyx Pharmaceutical Inc RARENCT06617429 Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Angelman Syndrometerminated129

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.